EOLS Stock Analysis: Evolus | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 435m USD | 12M Return: -31.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.95M
Qual. Beats: 1
Rev. Trend: 96.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 8.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Evolus, Inc. (EOLS) is a Newport Beach, California-based performance beauty company operating in the cash-pay aesthetic market across the United States, Canada, Europe, and Australia. The companys lead product is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation approved for the temporary improvement of moderate to severe glabellar lines (frown lines) in adults. Evolus also markets Evolysse, a line of injectable hyaluronic acid dermal fillers designed for areas such as the mid-face, nasolabial folds, lips, and eyes. Founded in 2012 and listed on Nasdaq since 2018, the company is classified within the Health Care sector and competes in the medical aesthetics space.
As a small-cap pharmaceuticals company, Evolus operates in the consumer-funded portion of medical aesthetics, where treatments are paid out-of-pocket rather than reimbursed by insurance. Its neurotoxin (Jeuveau) competes in the same category as established products like Botox, Dysport, and Xeomin, while its hyaluronic acid filler line (Evolysse) targets the broader dermal filler market alongside brands such as the Juvéderm and Restylane families.
- Jeuveau gains share against Botox in cash-pay aesthetics
- Evolysse injectable launch broadens product portfolio beyond neurotoxins
- International expansion into Europe and Australia drives revenue growth
| Net Income: -43.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.20 > 0.02 and ΔFCF/TA -6.21 > 1.0 |
| NWC/Revenue: 23.49% < 20% (prev 27.40%; Δ -3.91% < -1%) |
| CFO/TA -0.17 > 3% & CFO -36.6m > Net Income -43.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (65.2m) vs 12m ago 2.34% < -2% |
| Gross Margin: 65.55% > 18% (prev 67.86%; Δ -2.31% > 0.5%) |
| Asset Turnover: 139.1% > 50% (prev 129.1%; Δ 9.97% > 0%) |
| Interest Coverage Ratio: -1.21 > 6 (EBIT TTM -23.3m / Interest Expense TTM 19.3m) |
| A: 0.32 (Total Current Assets 138.9m - Total Current Liabilities 68.0m) / Total Assets 220.6m |
| B: -3.04 (Retained Earnings -671.7m / Total Assets 220.6m) |
| C: -0.11 (EBIT TTM -23.3m / Avg Total Assets 217.0m) |
| D: -0.12 (Book Value of Equity -28.8m / Total Liabilities 249.4m) |
| Altman-Z'' = -8.66 = D |
| DSRI: 1.00 (Receivables 52.2m/47.5m, Revenue 301.8m/275.5m) |
| GMI: 1.04 (GM 67.86% / 65.55%) |
| AQI: 0.94 (AQ_t 0.32 / AQ_t-1 0.33) |
| SGI: 1.10 (Revenue 301.8m / 275.5m) |
| TATA: -0.03 (NI -43.4m - CFO -36.6m) / TA 220.6m) |
| Beneish M = -2.96 (Cap -4..+1) = A |
As of July 14, 2026, the stock is trading at USD 6.52 with a total of 1,302,114 shares traded. Over the past week, the price has changed by -6.72%, over one month by -3.41%, over three months by +50.58% and over the past year by -31.44%.
Current recommended Stop Loss: 6.10 (which is 6.4% or 1.3 ATR below the current price).
Evolus has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy EOLS.
- StrongBuy: 4
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 14.7 | 125% |
P/E Forward = 60.241
P/S = 1.4424
P/B = 53.7058
Revenue TTM = 301.8m USD
EBIT TTM = -23.3m USD
EBITDA TTM = -14.0m USD
Long Term Debt = 156.4m USD (from longTermDebt, last quarter)
Short Term Debt = 2.55m USD (from shortTermDebt, last quarter)
Debt = 173.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 8.49m
Net Debt = 123.6m USD (calculated: Debt 173.4m - CCE 49.8m)
Enterprise Value = 558.9m USD (435.3m + Debt 173.4m - CCE 49.8m)
Interest Coverage Ratio = -1.21 (Ebit TTM -23.3m / Interest Expense TTM 19.3m)
EV/FCF = -12.82x (Enterprise Value 558.9m / FCF TTM -43.6m)
FCF Yield = -7.80% (FCF TTM -43.6m / Enterprise Value 558.9m)
FCF Margin = -14.44% (FCF TTM -43.6m / Revenue TTM 301.8m)
Net Margin = -14.39% (Net Income TTM -43.4m / Revenue TTM 301.8m)
Gross Margin = 65.55% ((Revenue TTM 301.8m - Cost of Revenue TTM 104.0m) / Revenue TTM)
Gross Margin QoQ = 64.75% (prev 65.66%)
Tobins Q-Ratio = 2.53 (Enterprise Value 558.9m / Total Assets 220.6m)
Interest Expense / Debt = 11.10% (Interest Expense 19.3m / Debt 173.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -18.4m (EBIT -23.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.04 (Total Current Assets 138.9m / Total Current Liabilities 68.0m)
Debt / Equity = -6.02 (negative equity) (Debt 173.4m / totalStockholderEquity, last quarter -28.8m)
Debt / EBITDA = -8.81 (negative EBITDA) (Net Debt 123.6m / EBITDA -14.0m)
Debt / FCF = -2.84 (negative FCF - burning cash) (Net Debt 123.6m / FCF TTM -43.6m)
Total Stockholder Equity = -24.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -20.01% (Net Income -43.4m / Total Assets 220.6m)
RoE = 174.9% (negative equity) (Net Income TTM -43.4m / Total Stockholder Equity -24.8m)
RoCE = -17.71% (EBIT -23.3m / Capital Employed (Equity -24.8m + L.T.Debt 156.4m))
RoIC = -13.14% (negative operating profit) (NOPAT -18.4m / Invested Capital 140.1m)
WACC = 8.76% (E(435.3m)/V(608.7m) * Re(8.76%) + D(173.4m)/V(608.7m) * Rd(11.10%) * (1-Tc(0.21)))
Discount Rate = 8.76% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.93 | Cagr: 5.94%
[DCF] Fair Price = unknown (Cash Flow -43.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.99 | # QB: 1
Revenue Correlation: 96.68 | Revenue CAGR: 23.00% | SUE: 0.21 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.04 | Chg30d=+0.00% | Revisions=-25% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.07 | Chg30d=+0.00% | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.09 | Chg30d=+0.00% | Revisions=+40% | GrowthEPS=+78.6% | GrowthRev=+11.2%
EPS next Year (2027-12-31): EPS=0.24 | Chg30d=+0.00% | Revisions=+17% | GrowthEPS=+355.3% | GrowthRev=+17.3%
[Analyst] Revisions Ratio: +18% (up=5, down=3)